Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Jun 08, 2023 6:25pm
222 Views
Post# 35487431

RE:RE:RE:RE:RE:They told you what they were going to do...

RE:RE:RE:RE:RE:They told you what they were going to do...jd, "If I was CEO, I wouldn't want me posting, either. I can't support management behaviour like Rathjen's. I was very concerned that because the Chiesi deal was so bad that Rathjen was deliberately trying to downgrade the apparent value of xB3..."

You loved the Chiesi deal and Rathjen, jd! YOU LOVED THEM!

Jul 01, 2020 jd celebrates Rathjen and the Chiesi deal:

"And it doesn't hurt that we finally have a CEO that can set serious goals and can execute on them. Plan yer work and work yer plan! Get's it done every time."

jd on July 2, 2020:


"What we do know is that the PhDs at Chiesi who are qualified to form opinions about xB3 have determined that xB3 is worth an investment, not only in upfront and potential milestone and royalty payments to Bioasis, but also in their own internal resources that are required to move 4 rare diseases through preclinical and clinical programs to commercialization.

That's a big validation of xB3, Bioasis and DrDR and I'm very happy with that. Bioasis has some money to move forward, to nail some real accomplishments down."

jd on July 8, 2020:


"All is good. Damn good. Real good."

jd on July 8, 2020:


"We get almost CDN $4 million up front (USD $3 million) and almost CDN $180 million in developmental, regulatory and commercial milestone payments. That's almost CDN $50 million per LSD.

What's wrong with you that you can't celebrate this incredible advancement for the company?"

jd on July 9, 2020:


"DrDR and her team are the first to actually get things done. They're running it. Good times at last and more to come."
<< Previous
Bullboard Posts
Next >>